Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...
Business Insider1d
Corcept Therapeutics (CORT) Receives a Buy from Truist Financial
Lee covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Argenx Se, and Wave Life Sciences. Currently, the analyst consensus on Corcept Therapeutics is a Strong Buy with an ...
The Pharma Letter1d
Corcept's Phase IV win changes mood music after ALS flop
US biotech Corcept Therapeutics (Nasdaq: CORT) has reported positive results from the Phase IV CATALYST study of Korlym ...
Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study
Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...
Le Lézard1d
XBeam from Xstrahl Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance for Use in the U.S.
Clearance for Use in the U.S. XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. XBeam is the ...
Le Lézard1d
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
QIAGEN today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI ...
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
FiercePharma1d
Corcept shows how excess cortisol might be pulling the strings in Cushing syndrome awareness campaign
Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...
devdiscourse2d
Health Sector Faces Challenges Amid Drug Trials, Legislation, and Climate Concerns
Recent developments in the health sector include a dosing pause in Keros Therapeutics' drug trial, Corcept Therapeutics' ALS ...
Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages
Canaccord Genuity analyst Edward Nash has maintained their bullish stance on CORT stock, giving a Buy rating on December 6.Pick the best ...
FierceBiotech2d
Corcept's cortisol modulator fails to slow ALS decline, linked to 'gastrointestinal upset' at onset
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...
Business Wire2d
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...